tiprankstipranks
Analyst Profile
Followed by 39 other investors
.
Scott Bardo

Scott Bardo

Berenberg Bank
Wall Street Analyst
Ranked #933 out of 8,047 Analysts on TipRanks (#1,592 out of 21,521 overall experts)

Success Rate

61%
129 out of 211 Profitable Transactions

Average Return

8.50%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Scott Bardo's ratings since 2016 and opened each position for the duration of 1 Year:
61.14% of your transactions would have been profitable with an average return of 8.5%

Stock Rating Distribution

405Ratings
68.15% Buy
25.19% Hold
6.67% Sell
Distribution of Scott Bardo's ratings

Additional Information

Main Sector:Services
Geo Coverage:
United KingdomUK Market
United StatesUS Market

Best Rating

Stock:
STRATEC Biomedical
(GB:0RAR)
Rating Type:Buy
Dates:Mar 26, 2020 - Feb 18, 2021
Gain:96.50%
The most profitable rating made by Scott Bardo

Scott Bardo's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Novartis
Buy
Reiterated
100%
+11.10%
1
Bayer
Buy
Reiterated
€104.25
(93.34% Upside)
0%
-7.90%
1
Merck KGaA
Buy
Reiterated
€99.38
(-45.90% Downside)
100%
+10.30%
1
Koninklijke Philips
Buy
Reiterated
$41.05
(103.14% Upside)
83%
+10.37%
7
MDxHealth SA
Hold
Reiterated
$1.49
(112.60% Upside)
0.00%
1
Siemens
Buy
Reiterated
€43.00
(-60.87% Downside)
80%
+4.92%
8
Fresenius SE & Co. KGaA
Buy
Reiterated
€59.50
(141.67% Upside)
75%
+0.30%
4
Fresenius Medical Care AG & Co. KGaA
Buy
Reiterated
€88.30
(139.00% Upside)
50%
+5.40%
2
Coloplast A/S
Sell
Reiterated
kr860.00
(1.43% Upside)
10%
-24.92%
15
IP Group plc
Buy
Reiterated
148.00p
(80.54% Upside)
0%
-27.20%
1
List of latest recommendations made by Scott Bardo. Click to expand and see Scott Bardo's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More